March 6, 2018 / 11:01 AM / 3 months ago

BRIEF-Glaxosmithkline New Data From Phase III Clinical Trial With Fluarix Tetra

March 6 (Reuters) - Glaxosmithkline Plc:

* ANNOUNCED NEW DATA FROM PHASE III CLINICAL TRIAL WITH FLUARIX TETRA WHICH PREVENTED INFLUENZA A AND B IN CHILDREN 6 TO 35 MONTHS OF AGE‍​

* STUDY MET ITS TWO PRIMARY ENDPOINTS

* ‍STUDY ALSO FOUND THAT IIV4 REDUCED IMPACT OF INFLUENZA ON HEALTHCARE UTILISATION AND DAILY ACTIVITIES​

* FLURIX TETRA EFFICACY AGAINST MODERATE-TO-SEVERE INFLUENZA WAS 77.6% Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below